+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging



Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging



Radiology 178(1): 73-78



Manganese(II)-N,N'-dipyridoxylethylenediamine-N,N'-diacetate-5,5'-bis (phosphate) (MnDPDP) is a paramagnetic complex designed for use as a hepatobiliary agent. The T1 relaxivity of MnDPDP (2.8 [mmol/L]-1.sec-1 in aqueous solution) was similar to that of gadolinium diethylenetriaminepentaacetic acid (DTPA) (4.5 [mmol/L]-1.sec-1) and gadolinium tetraazocyclodecanetetraacetic acid (DOTA) (3.8 [mmol/L]-1.sec-1). However, in liver tissue the T1 relaxivity of MnDPDP (21.7 [mmol/L]-1.sec-1) was threefold higher than that reported for Gd-DOTA (6.7 [mmol/L]-1.sec-1). Maximum liver T1 relaxation enhancement occurred 30 minutes after injection of MnDPDP, at which time 54MnDPDP biodistribution studies indicated that 13% of total body activity was in the liver. Enhanced (MnDPDP, 50 mumol/kg) MR images showed a fivefold increase in tumor-liver contrast-to-noise ratio over baseline unenhanced images. Results of the authors' acute and subchronic toxicity studies suggest that MnDPDP will be safe at the doses necessary for clinical imaging; at 10 mumol/kg, the safety factor (LD50/effective dose) for MnDPDP is 540, significantly greater than the safety factor of Gd-DTPA (ie, 60-100).

(PDF emailed within 0-6 h: $19.90)

Accession: 041031309

Download citation: RISBibTeXText

PMID: 1898538

DOI: 10.1148/radiology.178.1.1898538


Related references

Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 183(1): 59-64, 1992

Preclinical evaluation of Fe-(5-C2H5-EHPG)- as a contrast agent in MR imaging of hepatobiliary system. Kaohsiung Journal of Medical Sciences 13(2): 75-85, 1997

Preclinical evaluation of gadolinium (III) texaphyrin complex. A new paramagnetic contrast agent for magnetic resonance imaging. Investigative Radiology 29(3): 330-338, 1994

Pulse sequence optimization for MR imaging using a paramagnetic hepatobiliary contrast agent. Radiology 157(2): 461-466, 1985

Imaging characteristics of DHOG, a hepatobiliary contrast agent for preclinical microCT in mice. Academic Radiology 15(3): 342-349, 2008

Preclinical evaluation of severely defective manganese-based nanocrystal as a liver-specific contrast media for MR imaging: comparison with Gd-EOB-DTPA and MnDPDP. Nanotechnology 29(22): 225101, 2018

MnDPDP as a negative hepatic contrast agent: evaluation of STIR imaging compared with T1-weighted SE and GE techniques. Journal of Computer Assisted Tomography 21(1): 94-99, 1997

Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging. Acta Radiologica 38(4 Pt 2): 660-664, 1997

Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195(3): 785-792, 1995

Evaluation of [Gd(Bz-TTDA)]2- as a potential contrast agent in MR imaging of the hepatobiliary system: an animal study. Journal of Magnetic Resonance Imaging 20(4): 632-639, 2004

Evaluation of manganese-trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetate complex (Cyclomang) as paramagnetic contrast agent for magnetic resonance imaging. Eksperimental'naia i Klinicheskaia Farmakologiia 76(10): 32-38, 2014

Preclinical investigation of Mn(II)-diethylenetriaminepentaacetate (Mangapentetate) as paramagnetic contrast agent for magnetic resonance tomography. Eksperimental'naia i Klinicheskaia Farmakologiia 71(4): 41-6; Discussion 47-8, 2008

Synthesis and Evaluation of Manganese(II)-Based Ethylenediaminetetraacetic Acid-Ethoxybenzyl Conjugate as a Highly Stable Hepatobiliary Magnetic Resonance Imaging Contrast Agent. Bioconjugate Chemistry 29(11): 3614-3625, 2018

Hepatobiliary MR imaging: first human experience with MnDPDP. Radiology 178(1): 79-82, 1991

Hepatobiliary imaging using a novel hepatocyte-selective CT contrast agent. Academic Radiology 9 Suppl 1: S194-S199, 2002